OSELLA ABATE, Simona

OSELLA ABATE, Simona  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 137 (tempo di esecuzione: 0.033 secondi).
Titolo Data di pubblicazione Autore(i) File
1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed? 2012 Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo
ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas 2018 Osella-Abate, Simona; Mereu, Elisabetta; Pellegrino, Elisa; Bergaggio, Elisa; Ribero, Simone; Bertero, Luca; Lisa, Francesco; Fierro, Maria Teresa; Papotti, Mauro Giulio; Piva, Roberto*
Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status: A Systematic Review and Meta-analysis 2015 Ribero, Simone; Gualano, Maria Rosaria; Osella-Abate, Simona; Scaioli, Giacomo; Bert, Fabrizio; Sanlorenzo, Martina; Balagna, Elena; Fierro, Maria Teresa; Macripò, Giuseppe; Sapino, Anna; Siliquini, Roberta; Quaglino, Pietro
Atypical mononuclear cells in “Neutrophilic Dermatitis” 1998 Tomasini C; Aloi F; Osella-Abate S; Novelli M
Blood Flow Cytometry in Sézary Syndrome: New Insights on Prognostic Relevance and Immunophenotypic Changes During Follow-up. 2015 Novelli M; Fava P; Sarda C; Ponti R; Osella-Abate S; Savoia P; Bergallo M; Lisa F; Fierro MT; Quaglino P.
BRAFi/MEKi in patients with metastatic melanoma: Predictive factors of complete response 2019 Ribero, Simone*; Malavenda, Ottavia; Fava, Paolo; Astrua, Chiara; Marra, Elena; Osella-Abate, Simona; Sanlorenzo, Martina; Caliendo, Virginia; Fierro, Maria Teresa; Quaglino, Pietro
Bullous pemphigoid is characterised by a reduction of skin-homing/circulating FOXP3+ Tregs and by a down-regulation of the IL-10 pathway 2012 Quaglino P; Antiga E; Novelli M; Nardò T; Fava P; Ponti R; Osella-Abate S; Caproni M; Fabbri P; Bernengo MG
Butyric acid effects on melanoma cell lines: apoptosis induction and cell cycle cytofluorimetric evaluation 1999 Salomone B; Cambieri I; Ponti R; Lisa F; Osella-Abate S; Ugazio E; Gasco M; Bernengo MG.
Caratterizzazione immunoistochimica e citofluorimetrica di una nuova linea di melanoma. 1998 Salomone B; Osella-Abate S; Fierro MT; Bernengo MG
CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients. 2001 FIERRO MT; NOVELLI M; SAVOIA P; CAMBIERI I; P. QUAGLINO; OSELLA-ABATE S; BERNENGO MG
CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma 2008 Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G.
Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients. 2012 Quaglino P; Antiga E; Comessatti A; Caproni M; Nardò T; Ponti R; Novelli M; Osella-Abate S; Fabbri P; Bernengo MG
Clinic-pathologic features of sentinel lymph nodes predictive for non-sentinel lymph node involvement, disease-free survival and overall survival in melanoma patients 2010 Quaglino P; Ribero S; Macri L; Sapino A; Osella-Abate S; Grassi M; Caliendo V; Savoia P; Sapino A; Macripò G; Bernengo MG
Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study 2012 Savoia P; Osella-Abate S; Deboli T; Marenco F; Stroppiana E; Novelli M; Fierro MT; Bernengo MG
Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data 2004 QUAGLINO P; SAVOIA P; FIERRO M; OSELLA-ABATE S; BERNENGO MG
Clinical significance of tyrosinase expression in the peripheral blood of stage III disease-free melanoma patient 2003 Fierro MT; Osella-Abate S; Savoia P; Quaglino P; Doveil GC; MG Bernengo
Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study. 2011 Quaglino P; Ribero S; Osella-Abate S; Macrì L; Grassi M; Caliendo V; Asioli S; Sapino A; Macripò G; Savoia P; Bernengo MG.
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. 2014 Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S.
Correlation between DNA-ploidy/cell cycle kynetics and histopathology in primary cutaneous B cell lymphomas 1999 Cambieri I; Ponti R; Quaglino P; Novelli M; Fierro MT; Osella-Abate S; Bernengo MG.
Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma 2020 Dika E.; Riefolo M.; Porcellini E.; Broseghini E.; Ribero S.; Senetta R.; Osella-Abate S.; Scarfi F.; Lambertini M.; Veronesi G.; Patrizi A.; Fanti P.A.; Ferracin M.